Bedrijfsoverzicht
AbCellera Biologics Inc. is a biotechnology enterprise dedicated to the discovery and development of antibody-based medicines designed to address unmet medical needs within the United States healthcare sector. Operating specifically within the biotechnology industry, the company focuses on therapeutic areas such as moderate-to-severe vasomotor symptoms, utilizing lead candidates like ABCL635 which is currently in Phase 2 clinical trials. The organization maintains a workforce of 562 employees and holds a total market capitalization of $1.07 billion, reflecting its position as a mid-to-large cap entity in the public markets. Despite a trailing twelve-month revenue of $75.13 million, the substantial market cap relative to annual sales suggests that investors are pricing the company based on the potential future value of its pipeline rather than current profitability, a common characteristic in early-stage biotechnology firms where clinical success drives valuation more than immediate earnings.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $75.13 million, while simultaneously posting a net income loss of $146.41 million and an EBITDA deficit of $194.93 million, highlighting a significant structural gap where operating expenses and clinical trial costs far exceed current sales revenue. This discrepancy indicates a cost structure heavily weighted towards research and development, where the primary expenditure is fueling the progression of assets like ABCL575 and ABCL635 through clinical stages rather than generating immediate profit margins. Free cash flow for the trailing twelve months stood at -$175.997 million, demonstrating that the company is burning cash at a rapid pace, which necessitates a reliance on existing cash reserves or external capital raises to maintain operations. The balance sheet shows a cash position of $533.83 million against total debt of $143.22 million, resulting in a debt-to-equity ratio of 14.81, which suggests a highly leveraged structure in nominal terms, though the strong cash buffer mitigates immediate solvency risks. The current ratio is an exceptionally high 11.32, indicating that the company holds a massive surplus of liquid assets relative to its current liabilities, providing a robust safety net against short-term obligations. Return on equity stands at -14.5% and return on assets at -10.0%, metrics that reveal that management is currently unable to generate positive returns on the capital base, a standard condition for pre-revenue or low-revenue biotech companies investing heavily in clinical development.
Waarderingsbeoordeling
The company exhibits a trailing P/E ratio that is effectively N/A due to losses, while the forward P/E is listed as -4.60, a metric that implies the market expects earnings to remain negative in the near term or that valuation models are relying on alternative drivers. A price-to-book ratio of 1.10 indicates that the market values the company at a slight premium over its book value, suggesting confidence in the quality of its intangible assets and pipeline potential despite current lack of profitability. The price-to-sales ratio is 14.28, and the EV/EBITDA is -3.50, both of which are alternative valuation metrics that suggest the company is being valued on a revenue multiple basis rather than earnings, typical for firms where future commercialization success is the primary value driver. The stock has a 52-week high of $6.51 and a low of $1.94; without a specific current price provided in the source data, the valuation range spans from a low of approximately 29.5% above the 52-week low to a high of roughly 30% below the 52-week high, illustrating the significant volatility inherent in the sector. With a beta of 0.85, the stock exhibits price volatility that is slightly lower than the broader market, indicating that the share price tends to move with less intensity than the overall market index during periods of fluctuation.
Growth & Income
Revenue growth for the trailing twelve months reached an impressive 788.2% year-over-year, whereas earnings growth is N/A due to the company's continued losses, implying that the expansion in sales is currently being consumed entirely by increasing operational and clinical costs rather than contributing to net income. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are not distributed to shareholders but are instead retained to fund research, development, and the clinical trials of its lead products. This strategy of reinvesting earnings into growth rather than paying dividends is characteristic of the biotechnology industry, where capital preservation and pipeline advancement take precedence over shareholder income distributions. The overall growth and income profile reflects a high-risk, high-reward dynamic where rapid revenue expansion is prioritized to achieve clinical milestones, with no current income generation for shareholders to rely upon.